Secondary oligomenorrhoea or amenorrhea in DMPA users. Secondary oligomenorrhoea
Conditions
Interventions
Intervention 1: Placebo of Fennelin capsule twice a day with placebo of LD tablet once a day for 21 days. Intervention 2: Fennelin capsul-100 mg- twice a day with placebo of LD tablet once aday for 2
Placebo
Treatment - Drugs
Placebo of Fennelin capsule twice a day with placebo of LD tablet once a day for 21 days
Fennelin capsul-100 mg- twice a day with placebo of LD tablet once aday for 21 days
LD tablet- 30 microgram ethinylestradiol and150 microgram levonorgestrel- once a day with placebo of Fennelin capsul twice a day for 21 days
Sponsors
Research Deputy of Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Having no or a little menstrual bleeding (bleeding score of 5 or less on the basis of Higham chart in day with maximum amount of bleeding) within 40-100 days. 2- Living in Tabriz city, Iran. and 3-Signing informed consent to take part in the study. Exclusion criteria: 1- No access to telephone. 2- Being pregnant. 3- Breastfeeding with less than 6 months old infant. 4-Intention to have a child in the following 3 months. 5- Less than 5 years education. 6- Known history of hyper or hypothyroidism, epilepsy, PCOS, diabetes, active mental disorders. 7- Known history of PID, tumor or fibroma. 8- Occurrence of important stressful event during 6 months. 9-Sensitivity to specific drugs or medical plants. and 10- Having contraindication of using oral contraceptive pills
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of blood loss. Timepoint: 15 days after the end of taking the drugs. Method of measurement: Pictorial blood loss assessment charts (Higham). | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events. Timepoint: 15 days after the end of taking the drugs. Method of measurement: self report.;Satisfaction in using DMPA. Timepoint: at baseline and 15 days following end of intervention. Method of measurement: self report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEnsiyeh Mohebbi-kian
Tabriz university of medical sciences
Outcome results
None listed